173 related articles for article (PubMed ID: 22338034)
1. Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin.
Salvatorelli E; Menna P; Gonzalez Paz O; Surapaneni S; Aukerman SL; Chello M; Covino E; Sung V; Minotti G
J Pharmacol Exp Ther; 2012 May; 341(2):474-83. PubMed ID: 22338034
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin.
Salvatorelli E; Menna P; Surapaneni S; Aukerman SL; Chello M; Covino E; Sung V; Minotti G
J Pharmacol Exp Ther; 2012 May; 341(2):464-73. PubMed ID: 22338033
[TBL] [Abstract][Full Text] [Related]
3. Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition.
Salvatorelli E; Guarnieri S; Menna P; Liberi G; Calafiore AM; Mariggiò MA; Mordente A; Gianni L; Minotti G
J Biol Chem; 2006 Apr; 281(16):10990-1001. PubMed ID: 16423826
[TBL] [Abstract][Full Text] [Related]
4. Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies.
Salvatorelli E; Menna P; Gianni L; Minotti G
J Pharmacol Exp Ther; 2007 Feb; 320(2):790-800. PubMed ID: 17135345
[TBL] [Abstract][Full Text] [Related]
5. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
[TBL] [Abstract][Full Text] [Related]
6. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
[TBL] [Abstract][Full Text] [Related]
7. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.
Salvatorelli E; Menna P; Paz OG; Chello M; Covino E; Singer JW; Minotti G
J Pharmacol Exp Ther; 2013 Feb; 344(2):467-78. PubMed ID: 23192654
[TBL] [Abstract][Full Text] [Related]
8. Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite.
Minotti G; Licata S; Saponiero A; Menna P; Calafiore AM; Di Giammarco G; Liberi G; Animati F; Cipollone A; Manzini S; Maggi CA
Chem Res Toxicol; 2000 Dec; 13(12):1336-41. PubMed ID: 11123976
[TBL] [Abstract][Full Text] [Related]
9. Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.
Sacco G; Giampietro R; Salvatorelli E; Menna P; Bertani N; Graiani G; Animati F; Goso C; Maggi CA; Manzini S; Minotti G
Br J Pharmacol; 2003 Jun; 139(3):641-51. PubMed ID: 12788824
[TBL] [Abstract][Full Text] [Related]
10. Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue.
Minotti G; Parlani M; Salvatorelli E; Menna P; Cipollone A; Animati F; Maggi CA; Manzini S
Br J Pharmacol; 2001 Nov; 134(6):1271-8. PubMed ID: 11704647
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulation in human heart.
Salvatorelli E; Menna P; Lusini M; Covino E; Minotti G
J Pharmacol Exp Ther; 2009 Apr; 329(1):175-84. PubMed ID: 19144686
[TBL] [Abstract][Full Text] [Related]
12. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.
Minotti G; Cavaliere AF; Mordente A; Rossi M; Schiavello R; Zamparelli R; Possati G
J Clin Invest; 1995 Apr; 95(4):1595-605. PubMed ID: 7706466
[TBL] [Abstract][Full Text] [Related]
13. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy.
Minotti G; Ronchi R; Salvatorelli E; Menna P; Cairo G
Cancer Res; 2001 Dec; 61(23):8422-8. PubMed ID: 11731422
[TBL] [Abstract][Full Text] [Related]
14. Low-Dose Anthracycline and Risk of Heart Failure in a Pharmacokinetic Model of Human Myocardium Exposure: Analog Specificity and Role of Secondary Alcohol Metabolites.
Salvatorelli E; Menna P; Chello M; Covino E; Minotti G
J Pharmacol Exp Ther; 2018 Feb; 364(2):323-331. PubMed ID: 29222131
[TBL] [Abstract][Full Text] [Related]
15. Amrubicin induces apoptosis in human tumor cells mediated by the activation of caspase-3/7 preceding a loss of mitochondrial membrane potential.
Hanada M; Noguchi T; Yamaoka T
Cancer Sci; 2006 Dec; 97(12):1396-403. PubMed ID: 16995876
[TBL] [Abstract][Full Text] [Related]
16. Uptake and intracellular distribution of amrubicin, a novel 9-amino-anthracycline, and its active metabolite amrubicinol in P388 murine leukemia cells.
Yamaoka T; Hanada M; Ichii S; Morisada S; Noguchi T; Yanagi Y
Jpn J Cancer Res; 1999 Jun; 90(6):685-90. PubMed ID: 10429662
[TBL] [Abstract][Full Text] [Related]
17. The redox regulation of intermediary metabolism by a superoxide-aconitase rheostat.
Armstrong JS; Whiteman M; Yang H; Jones DP
Bioessays; 2004 Aug; 26(8):894-900. PubMed ID: 15273991
[TBL] [Abstract][Full Text] [Related]
18. Human heart cytosolic reductases and anthracycline cardiotoxicity.
Mordente A; Meucci E; Martorana GE; Giardina B; Minotti G
IUBMB Life; 2001 Jul; 52(1-2):83-8. PubMed ID: 11795600
[TBL] [Abstract][Full Text] [Related]
19. Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin.
Noguchi T; Ichii S; Morisada S; Yamaoka T; Yanagi Y
Jpn J Cancer Res; 1998 Oct; 89(10):1061-6. PubMed ID: 9849586
[TBL] [Abstract][Full Text] [Related]
20. Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2010 Jan; 23(1):6-10. PubMed ID: 19954191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
